Identifying supply chain vulnerabilities

Johns Hopkins Bloomberg School of Public Health conducted an independent study, co-funded by a U.S. government agency, analyzing the competition and vulnerabilities in the global supply chain for US generic APIs.

Methodology

The researchers analyzed integrated API manufacturing and market performance data from Cortellis Product Intelligence to perform a systematic examination of generic APIs produced globally for the U.S. market.

Outcomes

The researchers concluded that:

- 1/3 of APIs were manufactured by a single facility, and another 1/3 were manufactured by two or three facilities.
- More than 1 in every 5 APIs reflected markets in which current FDA standards would have failed to detect low competition because there were three or fewer API manufacturers despite there being 4 or more manufacturers of finished generic drugs.
- Incentives in the U.S. may be needed to support API production to safeguard against supply-chain disruptions.

"Monitoring the API supply is crucial to identifying vulnerabilities in the US pharmaceutical supply chain and identifying drugs that could represent potential priorities for domestic production."

Source: Health Affairs

Learn how you can analyze your competition and supply chain vulnerabilities with Cortellis Product Intelligence

CASE STUDY

Find reliable sources of API with Cortellis Product Intelligence

Questions answered:

- ✓ Who has experience manufacturing my API?
- ✓ Are there sufficient suppliers available to manufacture my API?
- ✓ To which markets can this manufacturer supply?
- ✓ Who can serve as an alternate supplier in case there is a supply chain disruption?